Search
Breast Cancer Paid Clinical Trials in Massachusetts
A listing of 161 Breast Cancer clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
73 - 84 of 161
The state of Massachusetts currently has 161 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Featured Trial
Lung or Breast Cancer Treatment
Recruiting
Diagnosed w/ Lung or Breast Cancer - Underwent Cancer Treatment, Take a step towards hope and healing. Enroll now in our clinical trial for an innovative breast and lung cancer treatment
Conditions:
Cancer
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Healthy Volunteer Clinical Studies
Recruiting
Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.
Conditions:
Healthy
Healthy Volunteers
Featured Trial
Breast Cancer Study
Recruiting
If you have stage 4 breast cancer, you may be able to help advance medical research. Learn about DYNASTY-Breast02 Study enrolling now.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +4 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
Recruiting
This research is studying a new investigative imaging instrument called a nonlinear microscope (NLM). A nonlinear microscope can produce images similar to an ordinary pathologist's microscope, but without first processing tissue to make slides. This study will determine if a NLM can be used to evaluate tissue during lumpectomy surgery for breast cancer in order to reduce the probability that standard pathologic examination of the specimen after the end of the operation will find close or positiv... Read More
Gender:
Female
Ages:
21 years and above
Trial Updated:
05/07/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Breast Cancer
Testing Conversation Aid in Practice
Recruiting
The goal of this research study is to develop and test a website to help primary care providers (PCPs) discuss the pros and cons of mammography with women aged 75 and older and to help participants make decisions about mammography.
Gender:
Female
Ages:
Between 75 years and 89 years
Trial Updated:
05/07/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Breast Cancer
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Recruiting
This research study is studying a drug called GDC-0084 as a possible treatment for HER2-Positive Breast Cancer.
The drugs involved in this study are:
GDC-0084
Trastuzumab (Herceptin®)
Gender:
All
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
This study is seeking participants who have breast cancer that:
is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy
is sensitive to hormonal therapy (it is called estrogen receptor positive); and
is no longe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +3 locations
Conditions: Breast Cancer
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Recruiting
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 will focus on inoperable, locally advanc... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Recruiting
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab to subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Exelixis Clinical Site #25, Boston, Massachusetts
Conditions: Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
PRO1184 for Advanced Solid Tumors
Recruiting
This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors.
Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Triple Negative Breast Cancer, High Grade Epithelial Ovarian Cancer, Breast Adenocarcinoma, Hormone Receptor-positive/Her2 Negative Breast Cancer
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
Recruiting
This research is being done to determine whether acupuncture can help prevent or lessen chemotherapy-induced peripheral neuropathy (CIPN), a side effect of some kinds of chemotherapy that causes pain, numbness, tingling, swelling, or muscle weakness mostly in the hands or feet.
This research will also help determine whether acupuncture can improve quality of life in patients receiving taxane-based chemotherapy for the treatment of breast cancer.
The names of the study activities involved in th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Acupuncture, Early-stage Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
(VELA) Study of BLU-222 in Advanced Solid Tumors
Recruiting
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma, Advanced Solid Tumors, HR+ Breast Cancer
Peer Support For Young Adult Women With High Breast Cancer Risk
Recruiting
This trial will recruit young adult female relatives (YARs) of male or female carriers of BRCA1/2. YARs who consent to participate will be randomized to either a 3-session peer coach-led telephone counseling intervention or usual care navigation to peer support interventions provided by community organizations that support the hereditary cancer community. Study aims are to 1) Assess intervention effects on distress and decision making outcomes, including uptake of counseling for untested YARs, 2... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Dana Farber Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer Risk
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Recruiting
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors
73 - 84 of 161